New insights into synaptic vesicle dysfunction in Parkinson's disease.
1/5 보강
Parkinson's disease (PD) is characterized by progressive motor and non-motor dysfunction arising from synaptic pathology that precedes neuronal loss.
APA
Chlebowicz J, Ivanova V, Burré J (2026). New insights into synaptic vesicle dysfunction in Parkinson's disease.. Journal of Parkinson's disease, 1877718X261431203. https://doi.org/10.1177/1877718X261431203
MLA
Chlebowicz J, et al.. "New insights into synaptic vesicle dysfunction in Parkinson's disease.." Journal of Parkinson's disease, 2026, pp. 1877718X261431203.
PMID
41823255 ↗
Abstract 한글 요약
Parkinson's disease (PD) is characterized by progressive motor and non-motor dysfunction arising from synaptic pathology that precedes neuronal loss. Synaptic dysfunction represents a central pathological mechanism in both familial and sporadic PD, with multiple PD-linked genes directly regulating synaptic vesicle (SV) trafficking. Here, we review recent studies linking SV dysfunction to PD pathology by examining how disease-linked proteins dysregulate distinct steps in the SV cycle and by exploring their cascading effects on synaptic physiology and circuit function. We highlight three critical pathogenic mechanisms: (1) impaired neurotransmitter import and storage, (2) disrupted SV pool organization, and (3) altered SV exocytosis and endocytosis. We also review recent studies investigating how presynaptic pathology triggers impairments in postsynaptic plasticity and circuit-level reorganization across brain regions. Together, these studies highlight that presynaptic SV dysfunction is a central mechanism in PD pathogenesis and therefore a promising target for developing therapeutic strategies aimed at reverting these early disease-driving synaptic changes.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Clinical insight-driven novel drug development: Multidisciplinary integration and transformative opportunities.
- Obinutuzumab induces lysosomal destabilization via sphingomyelin-dependent inhibition of TRPML2.
- RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma.
- Inhibition of autoantigen-induced B-cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL).
- Small-molecule CBLB inhibitor abolishes EGFR ubiquitination, reduces receptor endocytosis, and diminishes cell motility signaling.
- Extracellular payload release from non-internalizing antibody-drug conjugates: mechanisms and linker technologies.